Overview

Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Recent News
Jan 3, 2023

—CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments— TEL AVIV, Israel, Jan. 3, 2023...

Dec 21, 2022

—Clean Safety Review Supports Addition of Higher Dose Cohort into the Trial— TEL AVIV, Israel, Dec. 21, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a...

Nov 30, 2022

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

Nov 14, 2022

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

All News

Stock Info
NASDAQCMMB
Events
Friday, November 11, 2022
8:00am EST

Virtual Webcast and Conference Call with Q&A
Senior Management will present
Listen to the Webcast

Conference call information:
US Investors: +1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference ID: 13732524
Ask for Chemomab conference call.

Wednesday, November 9, 2022 - Friday, November 11, 2022

Venue: Crowne Plaza Woburn, Woburn, MA
Format: Oral presentation: Crossing the Divide: Leveraging Fibrosis-Inflammatory Biomarkers to Inform Clinical Trial Design
Session: Illuminating the Latest in Fibrotic Biomarkers Across Indications to Harness Predictive and Progressive Biomarkers in Clinical Development
Time: November 10, 2022, 11:00 am ET
Presenter: Adi Mor, PhD, Co-Founder & Chief Scientific Officer, Chemomab
Information: https://afdd-summit.com/

A copy of the presentation will be available at the R&D section of Chemomab’s website (www.chemomab.com).

All Events

Featured Presentations

Download

Chemomab Corporate Overview - February 2023

 

Annual Report

Download

Chemomab 2021 Annual Report